Biologic Excipients Market Size, Share and Growth Analysis Report - Forecast Trends and Outlook 2026-2030

Biologic excipients are non-active formulation components such as stabilizers, surfactants, sugars, amino acids, polymers, and buffers that protect protein structure, solubility, and shelf-life in biologic drug products. The global market is currently worth approximately $7.2 billion in 2025 and is projected to grow at a compound annual rate near 5.85% through the next decade. Demand for these specialty ingredients is closely tied to the rising number of approved biologics and biosimilars, which require increasingly tailored formulation chemistries.

• •Estimated 2025 market value: around USD 7.2 billion
• •Forecast CAGR of approximately 5.85% through the early 2030s
• •Demand driven by monoclonal antibodies, vaccines, cell and gene therapies, and biosimilars

The principal engine of growth is the expanding global biologics pipeline, with more than 2,000 biologic candidates in development and a steady flow of monoclonal antibody and biosimilar approvals each year. Higher dosing concentrations and the shift toward subcutaneous self-administered biologics are pushing formulators toward more sophisticated stabilizers and surfactants. In parallel, regulators are tightening expectations around extractables, leachables, and endotoxin control, encouraging manufacturers to adopt higher-purity, specialty-grade excipients.

• •Rising biologics and biosimilar approvals increase excipient consumption per dose
• •Move toward high-concentration and subcutaneous formulations requires advanced stabilizers
• •Stronger regulatory scrutiny on purity, endotoxins, and extractables supports premium grades

By product category, the market spans polymers, sugars and sugar alcohols, polysorbates and other surfactants, amino acids, inorganic salts, and specialty chemicals such as chelators and antioxidants. By application, the largest share is consumed in monoclonal antibody and vaccine production, followed by cell and gene therapy manufacturing and biosimilar formulation. North America leads in consumption due to its concentration of biologic manufacturers, while Europe is a mature second region and Asia-Pacific is the fastest-growing as countries such as China, India, and South Korea expand local biomanufacturing capacity.

• •Polysorbates, sugars, and amino acids represent the largest product categories
• •Monoclonal antibodies and vaccines account for the majority of excipient consumption
• •Asia-Pacific is the fastest-growing regional segment due to expanding local biomanufacturing

What are the recent trends and outlook?

The next phase of growth is expected to come from excipients designed for emerging modalities, including lipid nanoparticles for mRNA delivery, viral vector stabilizers for gene therapies, and novel cryoprotectants for cell therapies. Manufacturers are also investing in animal-component-free, chemically defined ingredients to support safer and more reproducible bioprocessing. With biologics continuing to gain share of pharmaceutical sales and pipelines expanding across all major regions, the market is well positioned to maintain mid-single-digit annual growth through the early 2030s.

• •Rising demand for lipid nanoparticles, viral vector stabilizers, and cryoprotectants for advanced modalities
• •Shift toward animal-component-free and chemically defined excipients is accelerating
• •Mid-single-digit annual growth is expected to continue as biologics capture more of the pharmaceutical market